Alpha-Synuclein as a Biomarker of Parkinson’s Disease: Good, but Not Good Enough
Parkinson’s disease (PD) is the second most common neurodegenerative disorder of the elderly, presenting primarily with symptoms of motor impairment. The disease is diagnosed most commonly by clinical examination with a great degree of accuracy in specialized centers. However, in some cases, non-cla...
Main Authors: | Upasana Ganguly, Sukhpal Singh, Soumya Pal, Suvarna Prasad, Bimal K. Agrawal, Reena V. Saini, Sasanka Chakrabarti |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-07-01
|
Series: | Frontiers in Aging Neuroscience |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fnagi.2021.702639/full |
Similar Items
-
The Role of α-Synuclein Oligomers in Parkinson’s Disease
by: Xiao-yu Du, et al.
Published: (2020-11-01) -
The Role of Lipids in the Initiation of α-Synuclein Misfolding
by: Martin Kiechle, et al.
Published: (2020-09-01) -
Phosphorylation of Tau and α-Synuclein Induced Neurodegeneration in MPTP Mouse Model of Parkinson’s Disease
by: Hu S, et al.
Published: (2020-03-01) -
Characterization of α-synuclein oligomers formed in the presence of lipid vesicles
by: Anvesh K.R. Dasari, et al.
Published: (2024-07-01) -
Tau oligomers mediate α-synuclein toxicity and can be targeted by immunotherapy
by: Julia E. Gerson, et al.
Published: (2018-03-01)